This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk02: Welcome to the AccelRx third quarter 2022 earnings call. This call is being webcast live via the events page of the investor section of AccelRx's website at www.accelrx.com. This call is the property of AccelRx. And any recording, reproduction, or transmission of this call without the express written consent of AccelRx is strictly prohibited. As a reminder, today's webcast presentation is being recorded. You may listen to a replay of this webcast by going to the investor section of ExcelRx's website. I would now like to turn the call over to Rafi Azadorian, ExcelRx Chief Financial Officer.
spk06: Thank you for joining us on the call today.
spk07: This afternoon, we announced our third quarter 2022 financial results and associated business updates in a press release. This press release can be found within the Investors section of our website. With me today are Vince Angotti, our Chief Executive Officer, and Dr. Pam Palmer, Accelerex's founder and Chief Medical Officer. Before we begin, I want to remind listeners that during this call, we will make forward-looking statements within the meaning of the federal securities laws. These forward-looking statements involve risks and uncertainties regarding the operations and future results of Accelerex. Please refer to our press release in addition to the company's periodic, current, and annual reports filed with the Securities and Exchange Commission for a discussion of the risks associated with such forward-looking statements. I will now hand the call over to Vince.
spk05: Thank you, Rafi, and good afternoon, everyone. During the quarter and more recently, we've been focused on advancing our high-value development assets through the regulatory approval process, further reducing costs, and finding the best commercial partner for Desuvia. On the development front, we're pleased to report that as of this month, the initial development batch of NIAID has been successfully produced in preparation for a planned emergency use authorization targeted for the first half of 2023. In addition, we continue with our early commercial planning to ensure that we're prepared for a potential launch in NIAID next year. Our next focus will be to submit an NDA for our ephedrine pre-filled syringe, PFS01, planned by the end of this year. Our goal is to bring forward multiple potential new commercial products throughout next year. We continue with our efficient approach to managing cash in order to accomplish these important milestones. But even with this approach, including a significantly reduced commercial organization of only four people, we've been able to grow our Desudia sales with a year-over-year third quarter increase of 217% and a 51% increase year-to-date. We believe this is due to our strategic focus on getting Desudia adopted by procedural suite accounts and specifically in specialty settings such as plastic and cosmetic surgery, ENT, and oral maxillofacial. As a result, we're seeing an increased interest from large national accounts in these specialty areas. As previously disclosed, we're in active discussions with the larger, more resourced commercial organizations to potentially partner Desuvia to build upon our success and maximize Desuvia's value. We expect to finalize the transaction this quarter. Our European partner, Agaton, initiated its launch of Desuvio in Europe last month. Agaton will be implementing insights learned from our launch and commercialization of Desuvio in the U.S. to facilitate a broad and smooth rollout of Desuvio to physicians in the European markets. So let's move now to NIAID, our first ephemostat product that is being developed for use in the U.S. as an anticoagulant for extracorporeal circuits such as for use during dialysis. Now it is being regulated as a device by the FDA, given that its mechanism of action takes place outside of the body within the extracorporeal circuit to anticoagulate the circuit filter. The famostat is approved and widely used as an anticoagulant for dialysis in Japan and South Korea, and we're the first to develop it for such use in the United States. We plan to submit our EUA for NIAID to the FDA upon successful completion of our first CGMP lot production run and once stability data is available. Based on written feedback from the FDA, we're optimistic about the prospects of receiving this authorization given the recognized significant unmet medical need for patients undergoing continuous renal replacement therapy. In particular, the FDA has noted that certain healthcare facilities are ill-equipped for the use of citrate, the alternative EUA product for this indication. We believe NIAID could address a significant unmet need for the 60% of patients for whom existing anticoagulants like heparin or citrate are not used. We believe that citrate has many practical limitations due to safety risks and complexity of administration, yet due to the high and met need, it has been granted in EUA. As previously disclosed, the FDA assigned NIAID a breakthrough device designation, which provides us with several advantages as we work toward gaining regulatory approval, the most salient being additional FDA input during the development and submission processes as well as a priority review once an approval submission for the device has been filed. Furthermore, CMS has already assigned an ICD-10 procedural code from the Phamistats used in the extracorporeal circuit, and this will facilitate reimbursement for the product when it's commercially available. In addition, we plan to seek full FDA approval after conducting a single registrational study of 160 patients with endpoints that have already been agreed upon with the agency. As we stated in previous communications, we believe that the potential peak sales for NIAID could exceed $200 million annually as the only regional anticoagulant labeled for use in this indication in the U.S. And this is attributed to just the inpatient and outpatient dialysis markets, excluding use in any other extracorporeal circuits. Consistent with our priority to advance our pipeline of late-stage assets, we continue to progress toward filing NDAs for our ephedrine and phenylephrine pre-filled syringe product candidates, or PFS products, that we unlicensed from Agaton. Our lead candidate is PFS-01, or our ephedrine pre-filled syringe. The benefits of pre-filled syringes include less waste, improved safety, the convenience of not having to dilute and prepare the syringe in advanced procedures, and an improved shelf life. Based on Agaton's label, the expected shelf life of the ephedrine pre-filled syringe is three years. Again, we plan to submit the NDA for our first pre-filled syringe ephedrine by the end of this year, with a second following next year. With potential approval of an NDA for our ephedrine pre-filled syringe, commercialization could occur as soon as next year. As stated previously, we believe that the market opportunity for these assets exceeds $100 million, and we believe we'll be able to obtain a significant share of this market with minimal investment since much of the commercialization efforts are expected to be through contracting with group purchasing organizations and hospital networks. Now, before I hand the call over to Rafi, I want to reiterate our belief in the high market potential and medical promise for Desuvia and note the continued enthusiasm of researchers and key thought leaders. For example, in October, we announced a podium presentation made by Dr. Jeffrey DeWeese at Plastic Surgery, The Meeting 2022 held October 27th through the 30th. This was a presentation of an important study of Vesuvia investigated in a large cohort of plastic surgery procedures with significant results. This study entitled Experience in Complex Outpatient Plastic Surgery Procedures using sephentinal sublingual tablets, was conducted in 324 plastic surgery cases, and reported many positive benefits of Dissuvia, including, for example, the ability to perform complex, extensive cosmetic procedures without general anesthesia, allowing for a rapid discharge time. Also last month, we announced two abstracts that were presented at the Anesthesiology Annual Meeting 2022. The first abstract presentation was from a 190-patient investigator-initiated trial conducted at Brigham and Women's Hospital comparing the use of Desuvia versus intravenous opioids for the management of postoperative pain following spinal surgery. The study found that such patients had significantly lower reported postoperative pain scores when treated with Desuvia versus intravenous opioids. The second abstract presentation was by the Uniformed Services University of the Health Sciences, which is the nation's federal health sciences university. In this abstract, the authors recommend the adoption of Desuvia by the Department of Defense to improve pain management in the battlefield setting. These and other recent publications provide continued endorsement of the value of Desuvia, both for patients experiencing acute pain in the medically supervised setting, as well as for those serving in our military who would benefit from a more practical and safer alternative for acute pain management. In addition, Cleveland Clinic recently completed a study on the use of Desuvia in orthopedic surgery patients with publication expected in the coming months. Beyond the procedural suite setting, Desuvia's largest customer is the Department of Defense. This large customer has many different purchasing points across various areas of the armed services. In fact, other branches of the military, including the U.S. Air Force and U.S. Navy, have recently placed or initiated their first orders for D'Souvia. That said, we're still focused on the U.S. Army, knowing that the largest opportunity for D'Souvia is within their sets, kits, and outfits, or SKOs, for deploying troops. Throughout this past quarter, we have continued to conduct multiple meetings to support the DoD acquisition process. We believe that our efforts are finally gaining momentum to ensure D'Souvia's broader adoption within the U.S. Army. In the meantime, the Army continues to make purchases for their stockpiling program. I'll now hand the call over to Rafi to take you through the third quarter financial results. Rafi?
spk07: Thank you, Vince. Our financial position remains solid with $20.9 million in cash at September 30 and $7.4 million in senior debt. Our debt continues to reduce each quarter as we reach maturity in June 2023. Desuvia sales increased 217% from Q3 2021 and 51% compared to the nine months ended September 2021. Desuvia has continued to demonstrate growth in the procedural suite market with a very lean sales team consisting of only four total commercial headcount. We remain steadfast in our belief that Desuvia's full potential can be maximized by a partner with more resources. The adoption of Desuvia for use in procedural suites for specialties such as plastic surgery, oral maxillofacial, and ENT continues to remain the largest driver of Desuvia sales. The procedural suite market represented 74% of all commercial sales for Desuvia in the third quarter of 2022, increasing from 51% in the third quarter of 2021. We believe that the work performed to date with targeting procedural suites has provided our potential new commercial partner a platform for increased growth. We expect to finalize the transaction with a potential partner by the end of this year. Total net revenues in the third quarter of 2022 of $0.5 million declined $1.4 million compared to the same period in 2021 due to the recognition of $1.7 million in revenues in the third quarter of 2021 attributed to an upfront payment received related to our Desuvio European licensing agreement. We are excited to have Agatant launching Desuvio, as Desuvia is branded in Europe, which we believe will further support brand recognition here in the U.S. Excluding non-cash depreciation and stock-based compensation, our third quarter 2022 combined SG&A and R&D expenses were $5.7 million compared to $8.6 million in 2021. The decrease in combined SG&A and R&D expenses in Q3 2022 was mainly driven by lower personnel-related costs and a reduction in D'Souvia-related selling expenses. We continue to evaluate our existing cost structure for further potential savings to extend our cash runway. I'll now turn the call back over to Vince.
spk05: Thank you, Rafi. And I'd now like to open the line up for any questions you might have. Danielle?
spk02: We will now begin the question and answer session. To ask a question, you may press star, then 1 on your telephone keypad. If you're using a speakerphone, please pick up your hands up before pressing the keys. To withdraw your question, please press star, then 2. The first question comes from Brandon Foulkes of Canterford Sherald. Please go ahead.
spk08: Hi. Thanks for taking my questions, and congratulations on the progress. Maybe just firstly for me, you know, we're not that far from your end. So can you just elaborate about the visibility and how close you are to a deal in Dissouvia? And how should we think about the range of possibilities? Is this a complete divestment of Dissouvia you're pursuing or a number of potential specialty or subspecialty partnerships? Maybe I'll take the chance to move on to Nayar.
spk05: Yeah, we're going to have Raf answer that. He's been deeply involved with the, the participants in the discussion on Dissuvia.
spk07: Yeah, I think, Brandon, the structure is still a bit open, but the way we're seeing it is we would divest Dissuvia but maintain the long-term upside through some sort of milestones and royalty structure. And we're also in discussions to keep a piece of that where we would continue to sell in one of the main sectors. But that's all still being evaluated with the participants we're talking with right now.
spk08: Okay. No, I appreciate that, given the sort of sensitivity around this. That is helpful. So maybe just switching to NIAID. Firstly... Are any gating factors to the NIAID loss at this stage? Is it just stability? Have they been manufactured and put in stability or anything else we should think about there? And then along those same lines, how would you characterize your interactions with the FDA currently? I heard you're on track, so that's great. And then how should we think about timelines for review of this EUA? I think we've all been sucked in a little bit on the EUA and COVID. So can you just level set our expectations in terms of timelines on the EUA for NIAID in terms of review timelines?
spk05: Sure, Brandon. This is Vince. We'll start with the first portion of your question, which was on gating factors. Our direction from the FDA on gating factors was clearly around CMC. So that's where we put all of our efforts here in 2022. As mentioned, we've successfully produced our first test run of it, all specs being met. We're in the process right now of putting it up on stability with the final manufacturing run, so the clock will be moving on that. So we feel good about the CMC. I think one important factor is we're also evaluating multiple alternatives to manufacturing it on our own or synthesizing it on our own through other potential partners that could even potentially accelerate that EUA submission. So we're heading down multiple paths to be sure that we achieve our goals in early next year. Timelines for an EUA on how to think of that, you can't. I think it's all over the map based on everything we've researched and studied. They could happen quickly. They could take months. They might take more than months. I think it significantly depends on the disease state within which you're operating and how it's being affected by the current environment. I think importantly, we're actually working on some additional research and information here that Pam can comment on. in particular relative to physicians and what they're seeing with the current environment, how it's affecting them in continuous renal replacement therapy?
spk03: Yeah, we're conducting market research on 150 kidney specialists, intensivists, and really examining their issues with the current CRRT, anticoagulants, really looking at the impact that COVID has had. You know, HHS has just agreed to maintain COVID-19 public health emergency past January. It's still an issue. We don't know how bad this winter is going to be yet. So, you know, they've got issues. They've got CRT patients that need anticoagulation, and we are just thrilled to move this forward and really help these patients out, hopefully with that EUA.
spk05: So not a perfect answer on timelines of EUA because there is no standardization, but we're working aggressively to accelerate it as much as we can.
spk08: Great. Thanks so much. Maybe one more if I may, and then I'll hop back in the queue. Can you just update us on your conversations maybe with physicians in practice? Obviously, the fact that you're getting EOID is a significant need, but given that this product hasn't been on market for so many years, or never been on the market in the U.S., but ex-U.S., how difficult or how much work do you think there is to change EOID? habits and, you know, just treatment standards ahead of the ramp, but just once you've launched, you know, how quickly, I guess, do you think you can convert centers over to NIAID?
spk03: Yeah, Brandon. So, yeah, it's a small group of specialists. They really operate off of, you know, sort of colleague-to-colleague information, the guidelines. Certainly, we've been working with the folks who write the guidelines and We had an important sort of KOL call, I think it was last May, where Dr. Stuart Goldstein and Amin Chawla, you know, went over the advantages of nifamistat in a recent published study that showed the benefits of nifamistat over citrate by Dr. Goldstein. So, you know, it's a small group. They write the guidelines together. They all get together at meetings. And so word travels very fast. We're not looking at this being a huge commercial event. expense to get Nifamistat into these hospitals once the EUA is approved.
spk05: I think the other key consideration here is Nifamistat isn't a foreign term to them, meaning they understand through the education, watching what's happening internationally, that it's a standard of care in other markets. They just haven't had access to it here in the U.S. So the molecule Nifamistat, how it's being used, will not be a new concept, but it would certainly be a nice available concept to them moving forward.
spk08: Great, thank you very much. I appreciate you answering all my questions. Thank you, Brad.
spk02: The next question comes from Ed Arce from HC Wainwright. Please go ahead.
spk04: Hi, good afternoon, everyone. This is Thomas Yip asking a couple questions for Ed. Thank you for taking our questions. So first, I think for Rafi, since you're the point person for the Sylvia negotiations, What would you consider to be key elements of an optimal partnership and can you go over what are some potential impacts on ongoing partnership with the U.S. military?
spk07: Yeah, I think I obviously don't want to get into too much detail since we have not finalized the parties that we're discussing with. But I think the most important is having a partner that we're comfortable with that is going to do a great job and invest in Desuvia. We clearly believe in the product. We know we have not been able to resource it like we have wanted to. But we believe there is a lot of value still in this product. And it's evidenced by us being able to continue to grow sales with a very limited team. But that alone, that's why any structure that we have been discussing and will likely come out to will have a royalty and milestone structure that we can participate in the upside. And that's important for us. What's also important is maybe keeping a part of the business, and I don't want to get into any details, but keeping a part of that business that we think has upside for us, given the relationships that we've been able to develop in that market.
spk05: Yeah, I think it's important that the partner, to elaborate on what I've said just for a moment, they would already have a commercial organization or that type of structure that allows them to spread the cost of an additional product over that structure. whether it's the pharmacovigilance, et cetera, where for us it's just isolated to one product. So Rafi's done a nice job in sourcing those potential partners. Thomas, I think the second part of your question, was it about the DOD?
spk04: Yeah, that's right, and the potential or ongoing partnerships for DOD.
spk05: Yeah, so we have... We've been working with the DOD, you know, for years now. And we've just more recently actually had direct contact with their specific purchasers. Well, often historically it's gone through the wholesalers or middlemen, RQs, et cetera. Now we're being contacted directly by the military. And that's a nice change for us moving forward. Even though we've been working with other members of the military, these are the actual end user orderers of it. We also got our first indications of order from the Air Force and Navy and While they're not typically as large as the Army or with the potential of the Army, it's nice to see the additional branches starting to utilize or inquiry for D'Souvia based off of their addition or membership of the joint deployment formulary because of D'Souvia's availability to all military branches. So we feel good about that moving forward. It's been a lot of hard work behind the scenes, but now with these multiple different pathways of purchasing, either through the wholesaler or directly with us and some other avenues, we feel that the momentum is really beginning to pick up with the military.
spk04: Got it. Thanks for the additional details. And perhaps our next question for NIAID, for the EUA, should we expect to see any new supportive data ahead of a decision or either press release or medical conference?
spk03: Remember that we've got an agreement with the... Yeah, there's... We likely will publish the market research that we're doing, actually, with 150 key folks that use anticoagulation for CRRT reporting this data. We actually think it's going to be a robust enough research that we would publish that. But... No, we're not specifically moving forward for any additional data you'll see prior to the EUA, but we will have the registrational study right on the heels of that EUA submission where we're looking at 160 patients, a single registrational study to move towards, you know, the full approval of NIAID.
spk05: And Pam, maybe you can comment on the fact that that study in structure organization points has been Discussed already with the FDA.
spk03: Yes. The endpoints have been agreed upon. It's a very straightforward study. It's, you know, an anticoagulation, NIAID versus placebo, and the primary endpoint is, you know, activated clotting times. So it's a very straightforward study as far as we're concerned.
spk04: Thanks, Pam. Got it. And perhaps one final question from us regarding the peripheral syringe products. As we know, NIAID commercial prep is already underway. Any overlap there in terms of commercial infrastructure and preparations between these two product lines?
spk05: Yeah, as we evaluate NIAID for commercial launch, Pam mentioned to you it's pretty much a top-down approach from the key experts in the country that are all aware of the guidelines that they utilize. So that's not going to require much of a sales team relative to that. It's going to be more about education for those KEs top-down. Sales force for pre-filled syringe will really be limited more to contracting. Ephedrine and phenylephrine are very well-known molecules. They're used every day in surgical suites across the country. So it's not about convincing them on the molecules themselves, their standards of care. It's more about the group purchasing organizations and the integrated delivery networks, IDNs, and educating them on the availability of it through contracts moving forward. So this would be less traditional launches that you've typically seen with larger sales teams. This would be very small commercial organization focused on a few KEs in contracting moving forward, both of which will be limited in total scope from a number standpoint when you combine them. So we feel like it's going to be very efficient moving forward.
spk04: Got it. Thank you again for the kind of questions and looking forward to the EOA update. Thanks, Tom.
spk02: This concludes our question and answer session. I would like to turn the conference back over to Vince Angotti for closing remarks.
spk05: Thank you, Danielle, and thank you for joining us today and for your continued support of AccelerX. We're excited about the progress made with our pipeline of assets, the efficiency in our cost structure, the strategic direction for Dissuvia, as well as the multiple catalysts, potential catalysts, over the next year. And we will remain focused on driving long-term shareholder value. We look forward to answering any additional questions you may have offline, and again, look forward to sharing our future developments. Thank you again.
spk02: The conference is now concluded. Thank you for attending today's presentation. You may now disconnect.
Disclaimer